Vaxxas: Interim Data for Phase I Clinical Study of First Needle-Free COVID-19 Vaccine

 

• Encouraging interim results from Phase 1 human clinical trial show COVID-19 vaccine candidate, called HexaPro, to be safe and well tolerated with positive signals of antibody responses to SARS-CoV-2.
• HexaPro is a second-generation version of the spike proteins used in all U.S. approved COVID-19 vaccines, which has been modified to be more stable and immunogenic, giving potential coverage of all SARS-CoV-2 variants.
• Vaxxas’ proprietary HD-MAP patch has the potential to simplify vaccination logistics and administration by eliminating or reducing the need for refrigerated distribution and storage, and potentially enable self-administration.
• These interim study results will be presented at the 2023 BIO International Convention.

https://www.biospace.com/article/releases/vaxxas-announces-interim-results-from-phase-i-clinical-study-of-first-needle-free-covid-19-vaccine-delivered-using-proprietary-high-density-microarray-patch-hd-map-/